Servatus
Business Services · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
12-14 Lomandra Pl, Coolum Beach, Queensl...Phone Number
+61 753576830Website
www.servatus.com.auRevenue
$6.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Servatus
Founded in 2012, Perchwell currently has several prospective microbial-based drugs undergoing human clinical trials and is well underway in developing effective alternative treatments for debilitating autoimmune, inflammatory, gastrointestinal, and dermatological conditions. The company is headquartered in Coolum Beach, Queensland, Australia.Explore more
Servatus Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Servatus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Servatus is spiking on competitors!
Product Launch: Get notified when Servatus launches new products
Check if Servatus has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Servatus has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Servatus had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Servatus
Earning: See what the market has to say on Servatus recently announced quarterly report
Servatus, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Servatus
Find 3 more new buyers
Compare Similar Companies to Servatus
Compare insights from companies similar to Servatus, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Servatus is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Servatus is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Servatus.
Servatus financials insights
Gather financial insights about Servatus, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Unspecified
$7.5M
Servatus Tech Stack
A closer look at the technologies used by Servatus
See more technologies
Servatus News & Media
Servatus strengthens Board with appointment of biopharmaceutical division head at Boehringer Ingelheim, Dr Uwe Buecheler
New Board appointment deepens and consolidates Servatus' extensive commercial and scientific expertise for its global biotherapeutics programs Dr Buecheler joins as Non-Executive Director from leading pharmaceutical giant Boehringer Ingelheim in Germany, where he is both Senior Vice President and Senior Advisor Biopharmaceuticals to the Board of Directors +30 years at Boehringer Ingelheim, he leads the biopharmaceuticals business in Germany, Austria and US, and recently developed a new site in SServatus launches Australia's first human study into the effects of live biotherapeutics on insomnia
Study to look at the link between the gut microbiome and sleep, by treating patients who suffer from insomnia with live biotherapeutics Phase I/II trial will run during 2022, with results expected in 2023 Close to 15% of the Australian population suffer from insomnia, with sleep disorders costing the economy and society around $51 billion annually SYDNEY, March 23, 2022 /PRNewswire/ -- Servatus Ltd, an Australian biopharmaceutical company delivering leading novel autoimmune and microbiome therapServatus raises $7.5 million to advance autoimmune therapies with its microbial biotherapeutics clinical programs
Servatus has raised $7.5 million in an oversubscribed capital raise, with strong support from sophisticated shareholders Funds raised will underpin Servatus' live microbial and engineered protein biotherapeutics drug development Two Phase 1/2 clinical trials to launch shortly in Queensland, for insomnia and rheumatoid arthritis, complementing existing trials on-foot in inflammatory bowel disease (IBD), H. pylori infection and IBS-C / chronic constipation Servatus is a leader in microbiome basedServatus Biopharmaceuticals Joins Microbiome Therapeutics Innovation Group
WASHINGTON, March 29, 2021 /PRNewswire/ -- The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Australian Biotech company Servatus Biopharmaceuticals Ltd to its coalition of companies leading the research and development of FDA-approved microbiome...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Servatus
Sign Up For FreeTo access detailed company insights
Founded in 2012, Perchwell currently has several prospective microbial-based drugs undergoing human clinical trials and is well underway in developing effective alternative treatments for debilitating autoimmune, inflammatory, gastrointestinal, and dermatological conditions. The company is headquartered in Coolum Beach, Queensland, Australia.... Read More
